['stable coronary artery disease']
['act-246475', 'placebo']

        Main Inclusion Criteria:

          -  1. Signed informed consent prior to any study-mandated procedure.

          -  2. Male and female subjects aged from 18-85 years, inclusive.

          -  3. For women of childbearing potential: Negative urine pregnancy test at Visit 1 and
             at Visit 2 before randomization.

          -  4. Stable CAD defined by the presence of any of the following conditions:

               1. History of CAD with coronary artery stenosis on coronary angiogram ≥50%.

               2. Previously documented myocardial infarction occurring more than 3 months prior to
                  randomization.

          -  5. Antiplatelet background therapy stable for at least 1 month prior to randomization.

          -  6. Body weight ≥ 40.0 kg (88.2 lbs).

        Main Exclusion Criteria:

          -  1. Acute coronary syndrome, percutaneous coronary intervention or any intervention for
             peripheral artery disease within 3 months prior to randomization.

          -  2. Acute ischemic stroke or transient ischemic attack (TIA) within 3 months prior to
             randomization.

          -  3. Active internal bleeding, or medical history of recent (< 1 month) bleeding
             disorders or conditions associated with high risk of bleeding (e.g., clotting
             disturbances, gastrointestinal bleed, hemoptysis).

          -  4. Hemoglobin ≤ 10 g/dL at screening.

          -  5. Loss of at least 250 mL of blood within 3 months of screening.

          -  6. Use of anticoagulants (oral, parenteral) or fibrinolytic therapy within 24 h prior
             to screening (Visit 1).

          -  7. Known platelet disorders (e.g., thrombasthenia, thrombocytopenia, von Willebrand
             disease).

          -  8. Pregnant or breastfeeding women.
      